Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.36 |
| ▸ | BRD1 | O95696 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298556 | 0.89 | CDC7 (0.36) | IRAK4BRPF1BRD1SIRT2CDC7 | |
| SCHEMBL3304808 | 0.89 | IRAK4 (0.34) | IRAK4BRPF1BRD1 | |
| SCHEMBL3294658 | 0.89 | IRAK4 (0.33) | IRAK4DGAT1 | |
| SCHEMBL3305318 | 0.88 | IRAK4 (0.33) | IRAK4DGAT1 | |
| SCHEMBL3300638 | 0.88 | IRAK4 (0.33) | IRAK4DGAT1 | |
| SCHEMBL3297341 | 0.87 | IRAK4 (0.34) | IRAK4DGAT1 | |
| SCHEMBL3301537 | 0.87 | IRAK4 (0.32) | IRAK4DGAT1 | |
| SCHEMBL3300981 | 0.85 | IRAK4 (0.35) | IRAK4DGAT1 | |
| SCHEMBL3300532 | 0.85 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL3299451 | 0.85 | CCR9 (0.33) | IRAK4BRPF1BRD1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | IRAK4 2516/4885BRPF1 3781/4885BRD1 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.